Do analysts recommend TLSA or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, TLSA or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Tiziana Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Zhengye Biotechnology $16.64M 1.97 -$9.98M N/A N/A

Is TLSA or ZYBT more profitable?

Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A Zhengye Biotechnology N/A N/A N/A

Do analysts recommend ACOG or ZYBT?

Alpha Cognition currently has a consensus price target of $14.67, indicating a potential upside of 115.37%. Given Alpha Cognition's stronger consensus rating and higher possible upside, research analysts plainly believe Alpha Cognition is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ACOG or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Alpha Cognition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alpha Cognition $10.22M 14.51 -$20.67M -$1.35 N/A Zhengye Biotechnology $16.64M 1.97 -$9.98M N/A N/A

Do analysts prefer PYXS or ZYBT?

Pyxis Oncology currently has a consensus target price of $6.83, indicating a potential upside of 138.93%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe Pyxis Oncology is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, PYXS or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Pyxis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pyxis Oncology $13.86M 13.07 -$79.62M -$1.31 N/A Zhengye Biotechnology $16.64M 1.97 -$9.98M N/A N/A

Is PYXS or ZYBT more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Zhengye Biotechnology N/A N/A N/A

Do analysts prefer ZYBT or ENLV?

Enlivex Therapeutics has a consensus target price of $16.50, indicating a potential upside of 2,744.83%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enlivex Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, ZYBT or ENLV?

Enlivex Therapeutics has lower revenue, but higher earnings than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 1.97 -$9.98M N/A N/A Enlivex Therapeutics N/A N/A $1.24B -$0.55 N/A

Is ZYBT or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Zhengye Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Enlivex Therapeutics N/A 248.08% 206.39%

Do analysts rate ZYBT or HUMA?

Humacyte has a consensus price target of $6.25, suggesting a potential upside of 682.33%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Humacyte is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Humacyte 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has better earnings and valuation, ZYBT or HUMA?

Zhengye Biotechnology has higher revenue and earnings than Humacyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 1.97 -$9.98M N/A N/A Humacyte $2.04M 86.95 -$40.83M -$0.57 N/A

Zhengye Biotechnology (ZYBT) Competitors

$0.69 -0.02 (-2.97%)

Closing price 04:00 PM Eastern

Extended Trading

$0.73 +0.04 (+5.89%)

As of 07:53 PM Eastern

Compare

ZYBT vs. TLSA, ACOG, PYXS, ENLV, and HUMA

Should you buy Zhengye Biotechnology stock or one of its competitors? MarketBeat compares Zhengye Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zhengye Biotechnology include Tiziana Life Sciences (TLSA), Alpha Cognition (ACOG), Pyxis Oncology (PYXS), Enlivex Therapeutics (ENLV), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry.

How does Zhengye Biotechnology compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Tiziana Life Sciences has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.4, suggesting that its stock price is 340% less volatile than the broader market.

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 2 mentions for Zhengye Biotechnology. Tiziana Life Sciences' average media sentiment score of 0.63 beat Zhengye Biotechnology's score of 0.43 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Positive
Zhengye Biotechnology	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Zhengye Biotechnology	N/A	N/A	N/A

Zhengye Biotechnology has higher revenue and earnings than Tiziana Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Zhengye Biotechnology	$16.64M	1.97	-$9.98M	N/A	N/A

Summary

Tiziana Life Sciences beats Zhengye Biotechnology on 3 of the 5 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Alpha Cognition currently has a consensus price target of $14.67, indicating a potential upside of 115.37%. Given Alpha Cognition's stronger consensus rating and higher possible upside, research analysts plainly believe Alpha Cognition is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zhengye Biotechnology has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Zhengye Biotechnology's return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Zhengye Biotechnology	N/A	N/A	N/A

Alpha Cognition has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.4, indicating that its share price is 340% less volatile than the broader market.

In the previous week, Alpha Cognition had 1 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Alpha Cognition and 2 mentions for Zhengye Biotechnology. Alpha Cognition's average media sentiment score of 1.16 beat Zhengye Biotechnology's score of 0.43 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Cognition	Positive
Zhengye Biotechnology	Neutral

Zhengye Biotechnology has higher revenue and earnings than Alpha Cognition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	14.51	-$20.67M	-$1.35	N/A
Zhengye Biotechnology	$16.64M	1.97	-$9.98M	N/A	N/A

Summary

Alpha Cognition beats Zhengye Biotechnology on 7 of the 12 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, Pyxis Oncology had 1 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Pyxis Oncology and 2 mentions for Zhengye Biotechnology. Pyxis Oncology's average media sentiment score of 0.62 beat Zhengye Biotechnology's score of 0.43 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Pyxis Oncology	Positive
Zhengye Biotechnology	Neutral

39.1% of Pyxis Oncology shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pyxis Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.4, meaning that its stock price is 340% less volatile than the broader market.

Zhengye Biotechnology's return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Zhengye Biotechnology	N/A	N/A	N/A

Zhengye Biotechnology has higher revenue and earnings than Pyxis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	13.07	-$79.62M	-$1.31	N/A
Zhengye Biotechnology	$16.64M	1.97	-$9.98M	N/A	N/A

Pyxis Oncology currently has a consensus target price of $6.83, indicating a potential upside of 138.93%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe Pyxis Oncology is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Pyxis Oncology beats Zhengye Biotechnology on 9 of the 13 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Enlivex Therapeutics?

Zhengye Biotechnology (NASDAQ:ZYBT) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Enlivex Therapeutics has a consensus target price of $16.50, indicating a potential upside of 2,744.83%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics has lower revenue, but higher earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	1.97	-$9.98M	N/A	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A

1.0% of Enlivex Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Enlivex Therapeutics' return on equity of 248.08% beat Zhengye Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Enlivex Therapeutics	N/A	248.08%	206.39%

Zhengye Biotechnology has a beta of -2.4, indicating that its share price is 340% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

In the previous week, Zhengye Biotechnology and Zhengye Biotechnology both had 2 articles in the media. Enlivex Therapeutics' average media sentiment score of 0.62 beat Zhengye Biotechnology's score of 0.43 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Enlivex Therapeutics	Positive

Summary

Enlivex Therapeutics beats Zhengye Biotechnology on 10 of the 11 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Humacyte?

Zhengye Biotechnology (NASDAQ:ZYBT) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Zhengye Biotechnology has higher revenue and earnings than Humacyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	1.97	-$9.98M	N/A	N/A
Humacyte	$2.04M	86.95	-$40.83M	-$0.57	N/A

Zhengye Biotechnology has a beta of -2.4, indicating that its share price is 340% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market.

44.7% of Humacyte shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zhengye Biotechnology has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Zhengye Biotechnology's return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Humacyte	-4,836.06%	-2,914.18%	-89.45%

Humacyte has a consensus price target of $6.25, suggesting a potential upside of 682.33%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Humacyte is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Humacyte had 1 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Humacyte and 2 mentions for Zhengye Biotechnology. Humacyte's average media sentiment score of 0.79 beat Zhengye Biotechnology's score of 0.43 indicating that Humacyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Humacyte	Positive

Summary

Humacyte beats Zhengye Biotechnology on 9 of the 14 factors compared between the two stocks.

Get Zhengye Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYBT vs. The Competition

Export

Metric	Zhengye Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$32.80M	$3.65B	$6.84B	$12.44B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	N/A	21.29	25.83	24.36
Price / Sales	1.97	314.23	543.54	96.88
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.74	8.71	10.98	6.49
Net Income	-$9.98M	$23.87M	$3.57B	$336.61M
7 Day Performance	-3.51%	4.23%	3.06%	0.90%
1 Month Performance	-16.50%	1.71%	0.72%	-0.36%
1 Year Performance	-89.53%	69.92%	36.82%	31.26%

Zhengye Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYBT Zhengye Biotechnology	0.6325 of 5 stars	$0.69 -3.0%	N/A	-89.2%	$32.80M	$16.64M	N/A	278	Short Interest Increase
TLSA Tiziana Life Sciences	0.506 of 5 stars	$1.13 +0.9%	N/A	-26.3%	$143.80M	N/A	N/A	8
ACOG Alpha Cognition	4.0204 of 5 stars	$6.50 -1.2%	$14.67 +125.6%	-28.6%	$141.51M	$10.22M	N/A	N/A	Positive News
PYXS Pyxis Oncology	2.6786 of 5 stars	$2.23 +2.8%	$6.83 +206.4%	+151.8%	$141.27M	$13.86M	N/A	60
ENLV Enlivex Therapeutics	3.115 of 5 stars	$0.58 -4.1%	$16.50 +2,742.4%	-52.5%	$137.80M	N/A	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYBT) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. TLSA, ACOG, PYXS, ENLV, and HUMA

How does Zhengye Biotechnology compare to Tiziana Life Sciences?

Summary

How does Zhengye Biotechnology compare to Alpha Cognition?

Summary

How does Zhengye Biotechnology compare to Pyxis Oncology?

Summary

How does Zhengye Biotechnology compare to Enlivex Therapeutics?

Summary

How does Zhengye Biotechnology compare to Humacyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. TLSA, ACOG, PYXS, ENLV, and HUMA

How does Zhengye Biotechnology compare to Tiziana Life Sciences?

Which has more volatility and risk, TLSA or ZYBT?

Does the media prefer TLSA or ZYBT?

Do analysts recommend TLSA or ZYBT?

Is TLSA or ZYBT more profitable?

Which has higher earnings and valuation, TLSA or ZYBT?

Summary

How does Zhengye Biotechnology compare to Alpha Cognition?

Do analysts recommend ACOG or ZYBT?

Is ACOG or ZYBT more profitable?

Which has more risk and volatility, ACOG or ZYBT?

Does the media refer more to ACOG or ZYBT?

Which has preferable valuation & earnings, ACOG or ZYBT?

Summary

How does Zhengye Biotechnology compare to Pyxis Oncology?

Does the media favor PYXS or ZYBT?

Do institutionals and insiders hold more shares of PYXS or ZYBT?

Which has more risk & volatility, PYXS or ZYBT?

Is PYXS or ZYBT more profitable?

Which has preferable valuation & earnings, PYXS or ZYBT?

Do analysts prefer PYXS or ZYBT?

Summary

How does Zhengye Biotechnology compare to Enlivex Therapeutics?

Do analysts prefer ZYBT or ENLV?

Which has stronger valuation and earnings, ZYBT or ENLV?

Do insiders & institutionals have more ownership in ZYBT or ENLV?

Is ZYBT or ENLV more profitable?

Which has more risk & volatility, ZYBT or ENLV?

Does the media refer more to ZYBT or ENLV?

Summary

How does Zhengye Biotechnology compare to Humacyte?

Which has better earnings and valuation, ZYBT or HUMA?

Which has more risk and volatility, ZYBT or HUMA?

Do institutionals & insiders believe in ZYBT or HUMA?

Is ZYBT or HUMA more profitable?

Do analysts rate ZYBT or HUMA?

Does the media prefer ZYBT or HUMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools